Eptifibatide (Integrilin)
Jump to navigation
Jump to search
Introduction
Tradename: Integrilin.
Indications
- adjunctive agent with angioplasty (PTCA, PCI)
- indicated for patients who have undergone PCI
- may be useful for acute coronary syndrome
- without persistent ST segment elevation[2]
- only in conjunction with PTCA[5] Conraindications:
- renal failure, serum creatinine > 4.0 mg/dL[4]
- not recommended for patients with unstable angina or NSTEMI who have received dual antiplatelet therapy & are symptom free[4]
- administration prior to PCI
Dosage
0/5 ug/kg/min for 12 hours
Injection: 0.75 mg/mL
Mechanism of action
- inhibits glycoprotein IIb/IIIa receptor
More general terms
Additional terms
References
- ↑ Kaiser Permanente Northern California Regional Drug Formulary, 2000
- ↑ 2.0 2.1 Journal Watch 22(6):47, 2002 Boersma E, Harrington RA, Moliterno DJ et al Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002 Jan 19;359(9302):189-98 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11812552
- ↑ Giugliano RP, White JA, Bode C et al Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009 May 21;360(21):2176-90. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19332455
- ↑ 4.0 4.1 4.2 NEJM Knowledge+ Question of the Week. Nov 19, 2019 https://knowledgeplus.nejm.org/question-of-week/53/
- ↑ 5.0 5.1 Medical Knowledge Self Assessment Program (MKSAP) 16, 19 American College of Physicians, Philadelphia 2012, 2022